Nimesulide for acute pain treatment in rheumatological practice: why the niche is still occupied
https://doi.org/10.21518/2079-701X-2016-17-110-112
Abstract
The article tells about the potential of nimesulide in patients with acute pain caused by lesions of the musculoskeletal system. The pharmacodynamic characteristics, mechanisms of action and high safety profile allow to consider Nimesulide to be an effective and fast-acting remedy for acute pain and inflammation.
About the Author
M. S. Eliseev
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med, 2004, 140: 441-451.
2. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell, 2009, 139: 267-284.
3. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci, 2007, 10: 1361-1368.
4. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet, 2005, 365: 965-973.
5. Arendt-Nielsen L, Nie H, Laursen MB et al. Sensitization in patients with painful knee osteoarthritis. Pain, 2010, 149: 573-581.
6. Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther, 2005, 107: 139-154.
7. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int, 2012, 32: 1491-1502.
8. Sandrini G, Proietti Cecchini A, Alfonsi E et al. Effectiveness of nimesulide in pain. A neurophysiological study in humans. Drugs Today, 2001, 37: 21-29.
9. Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract Suppl, 2002, 128: 11-19.
10. Bernareggi A. Pharmacokinetics of nimesulide. Clin Pharm, 1998, 35(4): 247-274.
11. Bianchi M, Ferrario P, Balzarini P et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res, 2006, 34: 348-354.
12. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain, 2007, 23: 565-570.
13. Кудаева Ф.М., Елисеев М.С., Барскова В.Г., Насонова В.А. Сравнение скорости наступления анальгетического и противовоспалительного эффектов различных форм нимесулида и диклофенака натрия при подагрическом артрите. Тер. архив, 2007, 5: 35-40.
14. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 2016, 0: 1-14.
15. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs, 2003, 63(Suppl 1): 37-46.
16. Bianchi M, Broggini M, Balzarini P et al. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract, 2007, 61: 1270-1277.
17. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2- selective antiinflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine, 2000, 25: 1579-1585.
18. Wober W, Rahlfs VW, Büchl N et al. Comparative efficacy and safety of the non-steroidal antiinflammatory drugs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J Clin Pract, 1998, 52: 169-175.
19. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and metaanalysis of observational studies (the SOS project). Drug Saf, 2012, 35: 1127-1146.
20. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf, 2013, 22: 365-375.
21. Gulmez SE, Larrey D, Pageaux GP et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf, 2013, 36: 135-144.
22. Venegoni M, Da Cas R, Menniti-Ippolito F et al. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann I-st Super Sanita, 2010, 46(2): 153-157.
23. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J, 2006, 27(14): 1657-1663.
24. Arfè A, Scotti L, Varas-Lorenzo C et al. Nonsteroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ, 2016, 28(354): i4857.
25. Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesu lide is a selective COX-2 inhibitory, atypical non-steroidal antiinflammatory drug. Curr Med Chem, 2008, 15: 278-283.
26. Fanelli A, Romualdi P, Vigano’ R et al. Non-selec tive non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. Acta Biomed, 2013, 84: 1-7.
Review
For citations:
Eliseev MS. Nimesulide for acute pain treatment in rheumatological practice: why the niche is still occupied. Meditsinskiy sovet = Medical Council. 2016;(17):110-112. (In Russ.) https://doi.org/10.21518/2079-701X-2016-17-110-112
Views:
550
Email this article 